Signal Says Buy Options Insurance on This Biotech

Newly upgraded Exelixis stock could take a breather, if past is prologue

Mar 18, 2019 at 1:06 PM
facebook X logo linkedin

Exelixis, Inc. (NASDAQ:EXEL) shares are fresh off a new high, thanks to some upbeat analyst attention. Specifically, Morgan Stanley upgraded the biotech stock to "equal weight" from "underweight," and hiked its price target to $28 from $20, citing strong prescription trends among other reasons. However, if recent history is any indicator, EXEL bulls may want to consider buying options insurance to guard against a short-term pullback.

EXEL stock surged as high as $25.31 this morning, representing a new annual high. The stock has almost doubled since touching a two-year low of $13.42 in late October, with pullbacks contained by its 60-day moving average. More recently, EXEL last week barreled through recent congestion in the $23-$24 neighborhood. At last check, the security has trimmed its lead to 0.6% to trade at $24.67.

EXEL stock chart March 18

Meanwhile, Exelixis sports relatively inexpensive short-term option premiums right now. The stock's Schaeffer's Volatility Index (SVI) of 37% is higher than just 3% of all other readings from the past year, suggesting EXEL's near-term options are pricing in relatively low volatility expectations at the moment.

Since 2008, there have been six other times when EXEL shares were within 2% of a 52-week high and simultaneously sported an SVI in the bottom 20% of its annual range. After those signals, the stock was lower one-month later two-thirds of the time, averaging a loss of 5.77%, according to data from Schaeffer's Senior Quantitative Analyst Rocky White.

Against this backdrop, now could be an opportune time for Exelixis shareholders to pick up options insurance on the cheap. Specifically, traders should consider buying protective puts on EXEL, which would lock in an acceptable sale price for the shares, should they once again take a turn for the worse. From the security's current perch, another 5.77% pullback would put the biotech around $23.30 in mid-April.


Unlock Weekend Profits with Chris Prybal's Favorite Strategy Up +487.5% in 2024

With the markets going left, right, and sideways, you need to have a plan now more than ever. 

Expert Trader Chris Prybal is no stranger to volatility, and has mastered finding big stock rallies while other traders aren't looking over the weekend. Rallies that produced gains like +207% on RTX calls, +236% on MARA calls, and +238% on NET calls.

A few simple moves on Sunday at 7pm could be the “Secret Sauce” your portfolio needs to not just stay afloat, but make unprecedented gains in this turbulent market.

Don’t sit on the sidelines, beat the market with Chris Prybal's strategy. Join him now!